Arena Pharmaceuticals
17 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (NCT03996369) | Arena Pharmaceuticals | 2020-09-15 |
| A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT04162769) | Arena Pharmaceuticals | 2019-10-04 |
| Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (NCT04043455) | Arena Pharmaceuticals | 2019-07-24 |
| Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (NCT03945188) | Arena Pharmaceuticals | 2019-06-13 |
| Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis (NCT03155932) | Arena Pharmaceuticals | 2017-12-29 |
Track Arena Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.